Oncolytics Biotech® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer
RefinitivLess than 1 min read
Oncolytics Biotech Inc 
ONCY:
ONCOLYTICS BIOTECH® ALIGNS WITH FDA ON PIVOTAL STUDY DESIGN FOR PELAREOREP IN FIRST-LINE PANCREATIC CANCER
ONCOLYTICS BIOTECH INC - TO LAUNCH IMMUNOTHERAPY TRIAL IN PANCREATIC CANCER IN 2026
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news